TP53 and myelodysplastic syndrome: TP53 mutations occur in roughly 20% of lower-risk del(5q) cases and confer poor cytogenetic response, inferior survival, and increased risk of leukemic transformation, particularly when present as biallelic (multihit) lesions, which now reclassifies the disease as TP53-mutant MDS rather than true del(5q) [27].